Please ensure Javascript is enabled for purposes of website accessibility

Why Spero Therapeutics Shares Are Sliding Today

By Keith Speights – Sep 11, 2020 at 11:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pricing of a stock offering is causing the drugmaker's shares to fall.

What happened

Shares of Spero Therapeutics (SPRO -10.46%) are sliding today, down 9.5% as of 11:17 a.m. EDT, after the company announced the pricing of a public stock offering.

So what

On Wednesday, Spero announced that it planned to conduct a public offering of 8 million shares, including common stock and shares of non-voting Series D preferred stock. The biotech stock fell 12% on Thursday following the news.

Two scientists in a lab with one looking through a microscope

Image source: Getty Images.

But the slide continued today after Spero revealed that the shares in the public offering will be priced at $10. That's well below yesterday's closing price of $11.12 per share.

Such sell-offs on the heels of public stock offering announcements are common. The good news for Spero is that it expects to raise gross proceeds of around $80 million. The company intends to use this cash for funding the advancement of lead candidate tebipenem HBr and other pipeline candidates, as well as for working capital and other general business purposes.

Now what

Spero reported positive results from a phase 3 study of tebipenem HBr in treating adults with complicated urinary tract infection and acute pyelonephritis (kidney infection). The company plans to file for FDA approval of the antibiotic drug candidate in the second quarter of 2021.  

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Spero Therapeutics, Inc. Stock Quote
Spero Therapeutics, Inc.
SPRO
$1.97 (-10.46%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.